Eur Rev Med Pharmacol Sci 2021; 25 (5): 2161-2162
DOI: 10.26355/eurrev_202103_25203

Reply Letter – “Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis”

A. De Vito, G. Madeddu

Department of Medical, Surgical and Experimental Sciences, Unit of Infectious Diseases, University of Sassari, Sassari, Italy. giordano@uniss.it

Free PDF Download

To cite this article

A. De Vito, G. Madeddu
Reply Letter – “Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis”

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 5
Pages: 2161-2162
DOI: 10.26355/eurrev_202103_25203

Keywords Related articles:

  1. Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis
  2. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019
  3. Reply Letter – COVID-19 (Novel Coronavirus 2019) – Recent trends
  4. Viral kinetics and factors associated with rapid viral clearance during lopinavir/ritonavir-based combination therapy in non-severe COVID-19 patients
  5. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review